Dr. Traber is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6620 Main St
Houston, TX 77030Phone+1 713-798-2500Fax+1 713-798-2505
Education & Training
University of MichiganFellowship, Gastroenterology, 1986 - 1987
McGaw Medical Center of Northwestern UniversityFellowship, Gastroenterology, 1984 - 1985- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1981 - 1984
Wayne State University School of MedicineClass of 1981
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1993
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy Start of enrollment: 2020 Aug 18
Publications & Presentations
PubMed
- 43 citationsEnhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.Brendan D. Curti, Yoshinobu Koguchi, Rom Leidner, Annah S Rolig, Elizabeth Sturgill
Journal for Immunotherapy of Cancer. 2021-04-01 - 23 citationsGalectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunityElizabeth Sturgill, Annah S Rolig, Stefanie N. Linch, Courtney Mick, Melissa J Kasiewicz
Oncoimmunology. 2021-03-01 - 190 citationsEffects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal HypertensionNaga Chalasani, M. Abdelmalek, Guadalupe Garcia-Tsao, Raj Vuppalanchi, Naim Alkhouri
Gastroenterology. 2020-04-01
Press Mentions
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes on Long-Term Migraine Drug Data, Decision Day for Eton, 2 IPOsMay 27th, 2021- Selecta Biosciences, Inc. (SELB) Q3 2020 Earnings Call TranscriptNovember 6th, 2020
- Innovate Biopharmaceuticals Plans to Commence the First Ever Phase 3 Registration Trial in Celiac Disease in 1H 2019 and Announce Top-Line NASH Data with Drug Combinations by EASL 2019December 17th, 2018
- Join now to see all
Grant Support
- Regulation Of Intestine-Specific Gene TranscriptionNational Institute Of Diabetes And Digestive And Kidney Diseases1997–2001
- Core--Morphology FacilityNational Institute Of Diabetes And Digestive And Kidney Diseases1997–2001
- Molecular Mechanisms Of Intestinal DevelopmentNational Institute Of Diabetes And Digestive And Kidney Diseases1995–2001
- Caudal-Related Genes In Mouse Intestinal DevelopmentNational Institute Of Diabetes And Digestive And Kidney Diseases1996–2000
- Center For Digestive And Liver DiseasesNational Institute Of Diabetes And Digestive And Kidney Diseases1997–1999
- Training Program In Gastrointestinal SciencesNational Institute Of Diabetes And Digestive And Kidney Diseases1995–1998
- GI Tract Conf--Development, Differentiation, AdaptationNational Institute Of Diabetes And Digestive And Kidney Diseases1997
- Homeodomain Genes In Intestinal DevelopmentNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1997
- Regulation Of Intestine Specific Gene TranscriptionNational Institute Of Diabetes And Digestive And Kidney Diseases1992–1996
- University Of Pennsylvania Training In GastroenterologyNational Institute Of Diabetes And Digestive And Kidney Diseases1993–1994
- Intestinal And Colonic Cytochrome P450 Gene ExpressionNational Institute Of Diabetes And Digestive And Kidney Diseases1992–1993
- Intestinal And Colonic Cytochrome P450 Gene ExpressionNational Institute Of Diabetes And Digestive And Kidney Diseases1989–1992
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
